Browse > Article

Muscle Weakness after Repeated Injection of Botulinum Toxin Type A Evaluated by Dental Prescale  

Byun, Young-Sub (Department of Oral medicine, college of dentistry, Yonsei University)
Song, Ji-Hee (Department of Oral medicine, college of dentistry, Yonsei University)
Choi, Young-Chan (Department of Oral medicine, college of dentistry, Yonsei University)
Kim, Seong-Taek (Department of Oral medicine, college of dentistry, Yonsei University)
Publication Information
Journal of Dental Rehabilitation and Applied Science / v.26, no.1, 2010 , pp. 69-75 More about this Journal
Abstract
Botulinum toxin type A(BTX-A) has been applied successfully to treat masseteric hypertrophy. However it can cause muscle weakness. This study was designed to measure the change in maximum bite force(MBF) after BTX-A injection into human masseter muscle and to evaluate the influence of a booster(repeated) injection. Thirty volunteers completed 18-week follow-up and MBF was measured. At 18 weeks after the first injection, a booster injection was given to 14 patients and they were followed up until 18 weeks from the booster injection. The mean MBF was approximately 20% lower at 2 weeks than before the injection, and it recovered gradually after 4 weeks to return to the preinjection level at 12 weeks. The MBF differed significantly between before the injection and at 2, 4, and 8 weeks after the injection(p<0.05). In booster injection group(n=14),the MBF decreased markedly at 6 weeks(p<0.05),and it recovered gradually in 12 weeks. The MBF was significantly reduced after booster injection of BTX-A into the human masseter muscle. The degree of discomfort experienced by the subjects had little effect on normal mastication.
Keywords
muscle weakness; botulinum toxin type A; masseter muscle; booster injection;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Park, M. Y., Ahn, K. Y., Jung, D. S. Botulinum toxin type A treatment for contouring of the lower face. 2003;29:477-483.   DOI   ScienceOn
2 Choe, S. W., Cho, W. I., Lee, C. K., et al. Effects of botulinum toxin type A on contouring of the lower face. 2005;31:502-507;discussion507.   DOI
3 Kim, N. H., Chung, J. H., Park, R. H., et al. The use of botulinum toxin type A in aesthetic mandibular contouring. PlastReconstrSurg 2005;115:919-930.   DOI   ScienceOn
4 Blitzer, A., Brin, M. F., Keen, M. S., et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. ArchOtolaryngolHeadNeckSurg 1993;119:1018-1022.   DOI   ScienceOn
5 Carruthers, J. A., Lowe, N. J., Menter, M. A., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. JAmAcadDermatol 2002;46:840-849.   DOI   ScienceOn
6 Blitzer, A., Binder, W. J., Aviv, J. E., et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. ArchOtolaryngolHeadNeckSurg 1997;123:389-392.   DOI
7 Borodic, G. E., Ferrante, R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. JClinNeuroophthalmol 1992;12:121-127.   DOI
8 Rzany B,Dill-Muller D,Grablowitz D,Heckmann M,Caird D;German-Austrian Retrospective Study Group. Repeated botulinumtoxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. 2007;33:S18-25.   DOI   ScienceOn
9 Oshima, M., Middlebrook, J. L., Atassi, M. Z. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. ImmunolLett 1998;60:7-12.   DOI   ScienceOn
10 Clark, G. T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. PhysMedRehabilClinNAm 2003;14:727-748.   DOI   ScienceOn
11 Moore, A. P., Wood, G. D. The medical management of masseteric hypertrophy with botulinum toxin type A. BrJOralMaxillofacSurg 1994;32:26-28.   DOI   ScienceOn
12 To, E. W., Ahuja, A. T., Ho, W. S., et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. BrJPlastSurg 2001;54:197-200.
13 Jankovic, J., Brin, M. F. Therapeutic uses of botulinum toxin. NEnglJMed 1991;324:1186-1194.   DOI   ScienceOn
14 Yu, C. C., Chen, P. K., Chen, Y. R. Botulinum toxin a for lower facial contouring: a prospective study. AestheticPlastSurg 2007;31:445-451;discussion452.   DOI   ScienceOn
15 Alam, M., Dover, J. S., Klein, A. W., et al. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject. ArchDermatol 2002;138:1180-1185.   DOI   ScienceOn
16 Ahn, K. Y., Kim, S. T. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. PlastReconstrSurg 2007;120:1662-1666.   DOI   ScienceOn
17 Simpson, L. L. Botulinum toxin: a deadly poison sheds its negative image. AnnInternMed 1996;125:616-617.   DOI   ScienceOn
18 Carruthers, J. D., Carruthers, J. A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. JDermatolSurgOncol 1992;18:17-21.   DOI   ScienceOn
19 Borodic, G. E., Ferrante, R., Pearce, L. B., et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. MovDisord 9:31-39,1994.   DOI   ScienceOn
20 Kim, H. J., Yum, K. W., Lee, S. S., et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. 2003;29:484-489.   DOI   ScienceOn
21 Kim, J. H., Shin, J. H., Kim, S. T., et al. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurementsted tuman masseter muscle. PlastReconstrSurg 2007;119:711-717.   DOI   ScienceOn